CMMB vs. BCEL, GTBP, TMBR, ARAV, LSDI, ATHE, CMRA, IMNN, GHSI, and APGN
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Atreca (BCEL), GT Biopharma (GTBP), Timber Pharmaceuticals (TMBR), Aravive (ARAV), Lucy Scientific Discovery (LSDI), Alterity Therapeutics (ATHE), Comera Life Sciences (CMRA), Imunon (IMNN), Guardion Health Sciences (GHSI), and Apexigen (APGN). These companies are all part of the "pharmaceutical preparations" industry.
Chemomab Therapeutics (NASDAQ:CMMB) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
23.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 34.9% of Atreca shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 11.3% of Atreca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Atreca received 85 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 50.00% of users gave Chemomab Therapeutics an outperform vote.
Chemomab Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Atreca has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Chemomab Therapeutics' return on equity of -101.15% beat Atreca's return on equity.
In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.37 beat Atreca's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
Chemomab Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 695.64%. Atreca has a consensus price target of $10.75, indicating a potential upside of 4,125.63%. Given Atreca's stronger consensus rating and higher probable upside, analysts clearly believe Atreca is more favorable than Chemomab Therapeutics.
Summary
Atreca beats Chemomab Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Chemomab Therapeutics Competitors List
Related Companies and Tools